Martina Nanci

Pavia, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.

Journal: HemaSphere
Published: October 13, 2025

Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis.

Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis.

Journal: Clinical research in cardiology : official journal of the German Cardiac Society
Published: April 12, 2025

Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis.

Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis.

Journal: Journal of the American Heart Association
Published: December 24, 2024

Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis.

Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis.

Journal: JACC. CardioOncology
Published: December 17, 2024

Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study.

Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study.

Journal: HemaSphere
Published: November 17, 2024

Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis.

Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: July 11, 2024

A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.

A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.

Journal: Hematological oncology
Published: March 11, 2024

Development and Validation of Staging Systems for AA Amyloidosis.

Development and Validation of Staging Systems for AA Amyloidosis.

Journal: Journal of the American Society of Nephrology : JASN
Published: March 28, 2023

Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival.

Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival.

Journal: Blood
Published: March 17, 2022

An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.

An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.

Journal: Leukemia
Published: February 23, 2022

Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients.

Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients.

Journal: Clinical chemistry and laboratory medicine
Published: August 16, 2021
Showing 1-11 of 11

Last Updated: 09/26/2026